Edition:
United States

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

22.12USD
18 Aug 2017
Change (% chg)

$0.08 (+0.36%)
Prev Close
$22.04
Open
$21.83
Day's High
$22.41
Day's Low
$21.83
Volume
90,218
Avg. Vol
169,203
52-wk High
$29.41
52-wk Low
$15.50

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics qtrly loss per share $0.91
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Flexion Therapeutics Inc :Flexion therapeutics reports second quarter 2017 financial results and recent business highlights.Flexion therapeutics inc qtrly loss per share $0.91.  Full Article

Flexion Therapeutics qtrly loss per share $0.75
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Flexion Therapeutics Inc ::Flexion Therapeutics reports first quarter 2017 financial results and recent business highlights.Qtrly loss per share $0.75.  Full Article

Flexion Therapeutics announces pricing of $175 mln of senior notes
Wednesday, 26 Apr 2017 07:04pm EDT 

April 26 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of $175 million 3.375% convertible senior notes due 2024.Size of offering was increased by $50 million from previously announced offering size of $125 million.  Full Article

Flexion Therapeutics announces proposed convertible senior notes offering
Tuesday, 25 Apr 2017 04:01pm EDT 

April 25 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed convertible senior notes offering.Says to offer $125 million principal amount of convertible senior notes due 2024 in a private offering.Says to use net proceeds from notes offering for commercialization and manufacture of zilretta.  Full Article

Flexion reports year-end 2016 financial results
Thursday, 9 Mar 2017 04:01pm EST 

Flexion Therapeutics Inc : Flexion reports year-end 2016 financial results . Frederick Driscoll, chief financial officer, intends to retire effective March 31, 2017 . Driscoll will continue with company in an advisory capacity until his successor has been named .Commercialization plans on target for potential Q4 launch of zilretta.  Full Article

Flexion Therapeutics announces NDA for Zilretta accepted by U.S. FDA
Tuesday, 7 Feb 2017 07:30am EST 

Flexion Therapeutics Inc : Flexion Therapeutics announces new drug application for Zilretta™ (fx006) accepted by U.S. Food and Drug Administration .Flexion Therapeutics Inc - agency has established a user fee goal date under prescription drug user fee act (PDUFA) of October 6, 2017.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 16 Nov 2016 09:00am EST 

Flexion Therapeutics Inc : Says public offering of 3.60 million common shares priced at $18.00 per share .Flexion Therapeutics announces pricing of public offering of common stock.  Full Article

Flexion Therapeutics reports Q2 2016 financial results
Wednesday, 3 Aug 2016 04:01pm EDT 

Flexion Therapeutics : Reports Second Quarter 2016 financial results . Reported a net loss of $14.2 million for Q2 of 2016, compared to a net loss of $12.4 million for Q2 of 2015 .Following positive guidance from U.S. FDA planned New Drug Application (NDA) submission on track for Q4 of 2016.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 8 Jun 2016 09:00am EDT 

Flexion Therapeutics Inc : Flexion Therapeutics announces pricing of public offering of common stock .Says public offering of 5.50 mln common shares priced at $14.00/shr.  Full Article

Flexion Therapeutics expects to incur "significant losses for foreseeable future"
Tuesday, 7 Jun 2016 04:54pm EDT 

Flexion Therapeutics Inc : Anticipate that we will continue to incur significant losses for foreseeable future .As of March 31, 2016, had an accumulated deficit of $156.6 million.  Full Article

BRIEF-Flexion Therapeutics qtrly loss per share $0.91

* Flexion therapeutics reports second quarter 2017 financial results and recent business highlights